SAVANNAH, GA – CURE Childhood Cancer is investing $1.72 million in the Precision Medicine Program at Children’s Healthcare of Atlanta, bringing CURE’s total investment in childhood cancer research in 2026 to more than $7.42 million.
CURE helped launch the Precision Medicine Program at Children’s Healthcare in 2017 with an initial $4.5 million commitment. Since then, CURE has invested more than $17 million in precision medicine research aimed at giving children with cancer more individualized and effective treatment options.
“Precision medicine is about understanding as much as we can about an individual child’s cancer so we can make treatment more personal and more precise,” said Kristin Connor, CEO of CURE Childhood Cancer. “Genetic sequencing can reveal what is driving a tumor and identify treatments that are most likely to work. But precision medicine continues to evolve, giving doctors and researchers new ways to understand how a child’s cancer behaves, how it responds to treatment, and even how that child’s body may respond to certain medications.”
The impact is measurable. Among children whose sequencing results were evaluated through the program, nearly 80% had at least one finding that could inform their care, from identifying a potential targeted therapy to providing new information about diagnosis, prognosis, or an inherited cancer risk. For children with high-risk or relapsed cancers, that information can be especially important when standard treatments have stopped working or options are limited.
CURE’s new $1.72 million investment will continue advanced genetic testing for children with high-risk and relapsed cancers who may not otherwise have access to it, while also supporting research aimed at making treatment even more precise. Researchers will study tumor DNA found in the blood to help monitor a child’s cancer over time, examine how a child’s genes affect the way medications work in the body, and use laboratory models grown from tumor tissue to test promising therapies and learn why some cancers respond to treatment while others do not.
“For children with high-risk or relapsed cancers, we need better answers,” continued Connor. “This investment will help doctors make more informed decisions for children being treated today while also supporting research that can lead to better, more precise treatments in the future. That combination is exactly where CURE can make a meaningful difference.”
For more on CURE’s precision medicine investment, visit https://curechildhoodcancer.org/our-research/precision-medicine/
About CURE Childhood Cancer: Founded in 1975, Atlanta-based CURE Childhood Cancer is dedicated to conquering childhood cancer by funding targeted research and providing critical support to patients and families. CURE invests millions of dollars each year in research aimed at improving treatment and outcomes for children with cancer, while also helping families navigate the practical, financial and emotional challenges from diagnosis through survivorship or bereavement. For more information visit www.curechildhoodcancer.org.
Nationally recognized, APR is a premier PR and biz development resource for clients throughout Georgia & SC Lowcountry. #Savannah #PR #publicrelations